We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
- Authors
Yazdanpanah, Y; Fagard, C; Descamps, D; Taburet, A M; Colin, C; Roquebert, B; Katlama, C; Pialoux, G; Jacomet, C; Piketty, C; Bollens, D; Molina, J M; Chêne, G; ANRS 139 TRIO Trial Group
- Abstract
The introduction of 2 or 3 fully active drugs in human immunodeficiency virus (HIV)-infected patients receiving failing antiretroviral therapy is a key determinant of subsequent treatment efficacy. The aim of this study was to assess the safety and efficacy of a regimen containing raltegravir, etravirine, and darunavir/ritonavir for treatment-experienced patients infected with multidrug-resistant HIV.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Vol 49, Issue 9, p1441
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/630210